Human Recombinant MASP2 protein, His Tag (V2LY-0526-LY5467)

Götz, M. P., Skjoedt, M. O., Bayarri-Olmos, R., Hansen, C. B., Pérez-Alós, L., Jarlhelt, I., ... & Garred, P. (2023). Lectin pathway enzyme MASP-2 and downstream complement activation in COVID-19. Journal of Innate Immunity, 15(1), 122-135.

Mulinti, P., Diekjürgen, D., Kurtzeborn, K., Balasubramanian, N., Stafslien, S. J., Grainger, D. W., & Brooks, A. E. (2022). Anti-coagulant and antimicrobial recombinant heparin-binding major ampullate spidroin 2 (MaSp2) silk protein. Bioengineering, 9(2), 46.

Gao, T., Zhu, L., Liu, H., Zhang, X., Wang, T., Fu, Y., ... & Cao, C. (2022). Highly pathogenic coronavirus N protein aggravates inflammation by MASP-2-mediated lectin complement pathway overactivation. Signal Transduction and Targeted Therapy, 7(1), 318.

Damoah, C. E., Snir, O., Hindberg, K., Garred, P., Ludviksen, J. K., Brækkan, S. K., ... & INVENT Consortium. (2022). High levels of complement activating enzyme MASP-2 are associated with the risk of future incident venous thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 42(9), 1186-1197.

Elhadad, S., Chapin, J., Copertino, D., Van Besien, K., Ahamed, J., & Laurence, J. (2021). MASP2 levels are elevated in thrombotic microangiopathies: association with microvascular endothelial cell injury and suppression by anti-MASP2 antibody narsoplimab. Clinical & Experimental Immunology, 203(1), 96-104.

Lafayette, R. A., Rovin, B. H., Reich, H. N., Tumlin, J. A., Floege, J., & Barratt, J. (2020). Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy. Kidney international reports, 5(11), 2032-2041.

Gao, T., Hu, M., Zhang, X., Li, H., Zhu, L., Liu, H., ... & Cao, C. (2020). Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. MedRxiv, 2020-03.

García-Laorden, M. I., Hernández-Brito, E., Muñoz-Almagro, C., Pavlovic-Nesic, S., Rúa-Figueroa, I., Briones, M. L., ... & Rodríguez-Gallego, C. (2020). Should MASP-2 deficiency be considered a primary immunodeficiency? Relevance of the lectin pathway. Journal of clinical immunology, 40, 203-210.

Bibert, S., Piret, J., Quinodoz, M., Collinet, E., Zoete, V., Michielin, O., ... & Bochud, P. Y. (2019). Herpes simplex encephalitis in adult patients with MASP-2 deficiency. PLoS pathogens, 15(12), e1008168.

Meijides-Mejías, C., Castillo-González, W., Rodríguez-Pérez, J. A., Lombillo-Alfonso, F., Mirabal-Viel, A., Pérez-del-Vallín, V., & Dorta-Contreras, A. J. (2019). MASP-2: New evaluating parameters. Revista Cubana de Investigaciones Biomédicas, 38(1).

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols